Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BV100 in CRABC Infections (RIV-CARE)
NCT07431307Phase 2Not yet recruiting
- Sponsor
- BioVersys AG
- Start
- Jul 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of BV100 in pneumonia, bloodstream infection (BSI), bacterial meningitis, ventriculitis, sponsored by BioVersys AG. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
BV100
03
Conditions
pneumoniabloodstream infection (BSI)bacterial meningitisventriculitis
Beyond the preview
Go deeper on NCT07431307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07431307.